Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
A webcast of the presentation will be available on
If you are interested in meeting with the Milestone team during the conference, please reach out to your
About
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
Source: Milestone Pharmaceuticals Inc.